Key result
High on-treatment platelet reactivity linked to ~193% higher death or MI risk after clopidogrel discontinuation.
Why the study?
Does high on-treatment platelet reactivity predict death or myocardial infarction after planned discontinuation of clopidogrel in patients undergoing elective coronary stent implantation?
Cohort (n=765)
Does high on-treatment platelet reactivity predict death or myocardial infarction after planned discontinuation of clopidogrel in patients undergoing elective coronary stent implantation?
High on-treatment platelet reactivity predicts an increased risk of death or myocardial infarction within the first year after planned discontinuation of clopidogrel, but not thereafter.
Answers are grounded in this paper and cite their sources.
HTPR was associated with higher early MACE risk after clopidogrel discontinuation; should not change practice and leaves open need for randomized testing trials.
It is unknown whether the known association of high on-treatment platelet reactivity (HTPR) with worse clinical outcome in patients on clopidogrel following coronary stent implantation persists after planned discontinuation of clopidogrel. This study investigated the association of HTPR with major ischaemic events after planned discontinuation of clopidogrel. Consecutive patients undergoing elective coronary stent implantation after loading with clopidogrel 600 mg were followed for up to seven years (n=765). Platelet reactivity was tested on day 1 after coronary intervention. Clopidogrel was continued for six months after implantation of drug-eluting stents and for one month if only bare-metal stents were used. The combined primary endpoint was death of any cause or non-fatal myocardial infarction (MACE). HTPR was found in 217 of 765 patients (28 %). During a median follow-up of 5.7 years, the primary endpoint occurred in 145 subjects after planned discontinuation of clopidogrel. Patients with HTPR showed a higher incidence of MACE after discontinuation of clopidogrel. There was a significant interaction of HTPR and time following discontinuation of clopidogrel beyond one year (p for interaction 0.08). Landmark analyses confirmed that the association of HTPR and MACE was only significant within the first year (HR: 2.93, 95 %-CI 1.13-7.60, p=0.03), but not beyond the first year following discontinuation of clopidogrel (HR: 1.19, 95 %-CI 0.82-1.72, p=0.37). In conclusion, patients with HTPR persist to be at high risk for death or myocardial infarction even following planned discontinuation of clopidogrel. However, this association was only significant for the first year following discontinuation of clopidogrel.
No takes yet. Share an insight, caveat, or question.
Bömicke et al. (2017) conducted a cohort in Coronary stent implantation (n=765). High on-treatment platelet reactivity (HTPR) vs. Patients without HTPR was evaluated on Death of any cause or non-fatal myocardial infarction (MACE) (HR 2.93, 95% CI 1.13-7.60, p=0.03). High on-treatment platelet reactivity was associated with a higher risk of death or non-fatal MI within the first year after planned clopidogrel discontinuation.
Synapse has enriched 10 related papers. Consider them for comparative context: